Nagoya-Based Taiyo Calls Off Price Listing For 12 Drugs
This article was originally published in PharmAsia News
Executive Summary
Taiyo Pharmaceutical has decided not to seek price listing for 12 generic drugs as a measure to tighten its quality control system and restore public trust after a drug quality control scandal led to a halt in production
|
Taiyo Pharmaceutical has decided not to seek price listing for 12 generic drugs as a measure to tighten its quality control system and restore public trust after a drug quality control scandal led to a halt in production. Taiyo cited one of the reasons for the recent quality scandal is a rapid generic business growth and the sheer volume of products the company's Takayama factory manufactures. Each day, it produces 558 of its own generic drugs and contract manufactures 268 established products for other companies. The company concluded that the quality control issue is a direct result of a lack of sufficient systems to address the fast expanding production and decided to slow down the price listing for new drugs. Taiyo is known for being a one-stop generic drug maker with the largest product lineup in Japan. (Click here for more - Japanese language) "Taiyo Forgoes May Drug Price Listing And Vows To Review Drug Items Under Manufacturing And Marketing"--CB News (4/13/2010) |